Chronic heart failure
Conditions
Interventions
Experimental Group:Standardized treatment for chronic heart failure + Linggui Yangxin Decoction granules
Control Group:Standardized treatment for chronic heart failure + placebo granules
Sponsors
The First People's Hospital of Yunnan Province
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Patients must meet all the following criteria to be eligible for this study: 1) Aged 18-85 years, regardless of gender; 2) History of chronic heart failure for over 1 month or clinical findings of heart failure symptoms for over 1 month. Chronic heart failure diagnosis refers to the 'Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024'; 3) NYHA cardiac function classification II-III; 4) Traditional Chinese Medicine (TCM) syndrome differentiation of Yang deficiency and blood stasis, based on the 'Guidelines for TCM Diagnosis and Treatment of Chronic Heart Failure (2022)'; 5) Voluntary participation with informed consent signed;
Exclusion criteria
Exclusion criteria: 1) Patients who received implantable cardioverter defibrillator or cardiac resynchronization therapy within 12 weeks; 2) Complicated with acute coronary syndrome (within 30 days), cardiogenic shock, acute myocarditis, uncontrolled malignant arrhythmia, hypertrophic obstructive cardiomyopathy, constrictive pericarditis, cardiac tamponade, severe valvular disease requiring surgery, or pulmonary embolism; 3) Comorbidities including severe primary diseases of heart, liver, kidney, hematopoietic or metabolic systems, malignancies, jaundice, or hepatic/renal insufficiency; 4) Complicated with acute infections; 5) Uncontrolled hypertension (systolic blood pressure =180mmHg or diastolic blood pressure =110mmHg); 6) HIV antibody-positive, syphilis-positive, hepatitis B or C patients; 7) Worsening heart failure symptoms due to digitalis toxicity; 8) Women planning pregnancy, pregnant, or lactating; 9) Suspected or confirmed alcohol/drug abusers; 10) Allergic constitution or known/suspected allergy to study drugs; 11) Received other investigational drugs within 60 days prior to randomization; 12) Patients deemed by investigators as unable to complete or comply with study requirements (due to administrative or other reasons).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NYHA cardiac function classification; | — |
Secondary
| Measure | Time frame |
|---|---|
| N-terminal pro-B-type natriuretic peptide (NT-proBNP);TCM syndrome score;Echocardiogram;Minnesota Heart Failure Quality of Life Assessment;6-minute walk test; | — |
Countries
China
Contacts
Public ContactZhang Hong
The First People's Hospital of Yunnan Province
Outcome results
None listed